Last updated on April 24, 2014 at 5:30 EDT

Pivotal Announces Scientific Presentation At the 17th World Congress on Heart Disease Demonstrating Superiority of VASCAZEN(TM) Unique Formulation

August 9, 2012

WOODBRIDGE, ON, Aug. 9, 2012 /PRNewswire/ – Pivotal Therapeutics Inc. (OTCQX:PVTTF) (CNSX:PVO), a specialty pharmaceutical company with a focus on cardiovascular
health, is pleased to announce that data from a scientific study
related to the company’s product VASCAZEN(TM) concluded that highly purified Eicosapentaenoic acid (EPA) and
Docosahexaenoic acid (DHA) with a 6:1 ratio caused potent
endothelium-dependent relaxations of isolated blood vessels,
relaxations superior to that of other pure EPA:DHA ratios (1:1) and
only 100% EPA or only 100% DHA.

The study authored by F. Zgheel, M. Alhosin, C. Auger and V.B. 
Schini-Kerth, entitled The highly purified EPA:DHA 6:1 product evokes potent
endothelium-dependent relaxations of porcine coronary artery rings via
the redox-sensitive PI3-kinase/Akt-dependent phosphorylation of eNOS
was presented at the 17(th) World Congress on Heart Disease – Annual Scientific Sessions 2012 on
July 29(th  )in Toronto, Canada and will be presented at the European Society of
Cardiology (ESC) in Munich, Germany on August 27, 2012.

The scientific study conducted at the University of Strasbourg, Illkirch, France demonstrated
that a specific (EPA) and (DHA) ratio and purity are important factors
in the ability of Omega-3 products to cause endothelium-dependent
relaxations of coronary arteries.  “We are very excited that the VASCAZEN(TM) formulation was superior to the other existing commercial products in
the marketplace in terms of sustained coronary vasodilation (i.e.
increase of blood flow) which is important for patients with Coronary
Heart Disease who have compromised coronary vessels” stated Dr. George
Jackowski Chairman and Chief Scientific Officer of Pivotal Therapeutics

About Pivotal Therapeutics Inc.
With offices in Toronto, Canada and Boca Raton, Florida, Pivotal
Therapeutics is a publicly traded (OTCQX: PVTTF) (CNSX: PVO) specialty
pharmaceutical company with a focus on the treatment of cardiovascular
disease.  Pivotal Therapeutics’ lead product VASCAZEN(TM) is a prescription medical food formulated to meet the dietary Omega-3
deficient needs of patients with cardiovascular disease through
elevating (EPA) and (DHA) to levels associated with reduced risk of
cardiovascular complications.

VASCAZEN(TM) is a >90% pure, proprietary EPA:DHA fatty acid formulation, protected
by a series of both issued and pending US and foreign patents and
commercialized by prescription only.

OMAZEN(TM) is a >90% pure, proprietary EPA:DHA fatty acid formulation
commercialized for sale and distribution in Canada for the maintenance
of good health through elevating Omega-3 fatty acid levels. The unique
formulation and dosage will be available to patients and consumers who
realize the health benefits of Omega-3 supplementation with a quality

Disclosure Notice

The information contained in this document is as of August 9, 2012. This
press release contains forward-looking statements. Such forward-looking
statements are subject to a number of risks, assumptions and
uncertainties that could cause Pivotal’s actual results to differ
materially from those projected in such forward-looking statements.
These statements can be identified by the use of words such as “will”,
“anticipate”, “estimate”, “expect”, “project”, “forecast”, “intend”,
“plan”, “believe”, “project”, “potential”, and similar expressions with
any discussion of future operating or financial performance or events.
In particular, factors that could cause actual results to differ
materially from those in forward looking statements include the
following: Pivotal’s inability to obtain additional financing on
acceptable terms; growth in costs and expenses; inability to compete
with others who provide comparable products; risk that the Company’s
products will not gain widespread market acceptance; risks relating to
the Company’s ability to maintain its CSNX listing. Forward-looking
statements speak only as of the date made and are not guarantees of
future performance. The Company undertakes no obligation to publicly
update or revise any forward-looking statements contained in this
document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.

SOURCE Pivotal Therapeutics Inc.

Source: PR Newswire